Canada: IP Monitor - No Harm, No Foul: Establish Irreparable Harm Clearly When Seeking Interlocutory Injunctions

Federal Court denies interlocutory injunction for moving party's failure to provide sufficiently clear evidence that it would suffer irreparable harm if the injunction was not issued.


A recent case before the Federal Court, The Regents of the University of California et al v I-Med Pharma Inc1, reaffirmed that in order to establish irreparable harm when seeking an interlocutory injunction in the context of an action for patent infringement, sufficiently clear evidence demonstrating irreparable harm was necessary. In denying the motion for interlocutory injunction, Justice Manson made several interesting observations about the arguments presented by the moving party. Justice Manson also ordered the Plaintiffs to post security for costs.

The Plaintiff and moving party, TearLab Corporation (TearLab), is an exclusive licensee of Canadian Patent No. 2,494,540 (the '540 Patent), which is owned by the other Plaintiff in this case, the Regents of the University of California (University). The '540 Patent generally relates to diagnostic devices, systems, and methods for measuring the osmolarity of tears, said to be useful for diagnosing and treating dry eye disease.

TearLab sought an interlocutory injunction to prevent the Defendant, I-MED Pharma Inc (I-MED), from selling its ophthalmic medical device pending determination at trial on the issues of patent infringement and validity.
I-MED sought security for costs for defending the present interlocutory motion and the patent infringement action as neither TearLab nor the University are ordinarily resident in Canada.

Interlocutory injunction

The three-part test for an interlocutory injunction as outlined by the Supreme Court of Canada2 requires that TearLab establish:

1. a serious issue to be tried;

2. that it will suffer irreparable harm if the injunction is not granted; and

3. that the balance of convenience favours the granting of an injunction.

The Federal Court did not grant TearLab an interlocutory injunction. Justice Manson held that TearLab did not provide sufficiently clear evidence that it would suffer unquantifiable and irreparable harm if the injunction was not issued. TearLab presented four arguments, but was unsuccessful on all four fronts.

Harm to TearLab's goodwill and reputation

TearLab argued that I-MED's product might be inferior to TearLab's product, thereby causing irreparable harm by turning ophthalmologists off of TearLab's technology. Justice Manson ruled that the evidence in support of this argument was speculative and unclear, especially since I-MED's device was approved by Health Canada.

Loss of market opportunity

TearLab also argued that without an interlocutory injunction, it would suffer permanent loss of market share, loss of opportunity to increase its market share, and permanent damage to its goodwill and reputation. Again, Justice Manson held that this argument was unsubstantiated as TearLab's evidence was speculative. Justice Manson noted that TearLab relied heavily on American Cyanamid v Ethicon Ltd3, a 1975 House of Lords decision. While Justice Manson acknowledged that this decision was relevant, it did not trump more recent and relevant decisions of Canadian Courts.

Inability to quantify damages

TearLab argued that irreparable harm ensued from the impossibility of calculating lost sales, as there was no reasonable methodology available to quantify the Defendant's activities. I-MED's expert testified that either (i) an epidemiological model or (ii) a quantitative statistical model could be used to estimate damages.

TearLab's expert argued that the epidemiological model was not viable as additional data, research, and analysis were required to predict damages using the model. Justice Manson held that the non-viability of the epidemiological model was immaterial, as it could be used to calculate reasonable damages if no injunction were granted following trial.

TearLab's expert also criticized the statistical model proposed by I-MED's expert on the basis that future prediction based on TearLab's historical sales data was impossible. TearLab's expert argued that incomplete data, market complexities, and interrelated variables rendered the predicted damages by the statistical model inadequate. Justice Manson found that the evidence submitted by TearLab's expert was insufficient to constitute "clear and not speculative" evidence that actual unquantifiable harm would occur. Furthermore, Justice Manson held that after trial, there were ways of quantifying actual losses in monetary terms even if no injunction were granted. The incomplete information before I-MED's expert at this time would no longer be hypothetical after trial. Data from any intervening and unexpected future events could be incorporated into the statistical model to adjust the projection of losses. Justice Manson stated that "[t]heoretical complexity in calculation is not alone clear evidence that damages are not capable of reasonable quantification".4

Moreover, in rejecting TearLab's claim that its losses were unquantifiable, Justice Manson accepted I-MED's argument that TearLab's position was inconsistent. TearLab argued that, because of the unique nature of the market, its losses could not be quantified if an injunction were refused and it prevailed at trial. Yet, TearLab offered an undertaking to compensate I-MED for I-MED's losses if an injunction were granted and TearLab lost at trial. If I-MED's damages could be quantified if an interlocutory injunction were granted and I-MED prevailed at trial, he saw no reason why TearLab's damages could not be quantified in the opposite scenario.

Ability to pay damages was not properly before the Court

TearLab attempted to argue that I-MED would be unable to pay a monetary award after trial, notwithstanding that it neither alleged, nor led evidence on, this issue. TearLab served a direction to attend on an affiant from the Defendant, requiring him to bring voluminous financial information to his cross-examination. No such documents were produced. Justice Manson refused to draw an adverse inference as the issue was not pleaded in the motion or addressed in the evidence.

Security for costs

I-MED brought a motion for security for costs. Justice Manson followed a trend that requires substantial security to be posted in stages and ordered TearLab (which has virtually no assets in Canada) to post $100,000 through the discovery process with I-MED entitled to seek additional security later in the proceedings.

This decision by the Federal Court reaffirms that it is generally difficult for a moving party seeking an interlocutory injunction to sufficiently and clearly establish that it will experience irreparable harm if the injunction is not granted.

TearLab has appealed the decision.

Link to decision:

2016 FC 606

Footnotes

1 2016 FC 606.

2 RJR-MacDonald Inc v Canada (Attorney General), [1994] 1 SCR 311 at 347-349.

3 [1975] RPC 13 at 542.

4 The Regents of the University of California et al v I-Med Pharma Inc, 2016 FC 606 at para 70.


About Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

For more information about Norton Rose Fulbright, see nortonrosefulbright.com/legal-notices.

Law around the world
nortonrosefulbright.com

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions